Asunaprevir
- Generic Name
- Asunaprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C35H46ClN5O9S
- CAS Number
- 630420-16-5
- Unique Ingredient Identifier
- S9X0KRJ00S
- Background
Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercializati...
- Indication
Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.
...
- Associated Conditions
- Chronic Hepatitis C Genotype 1, Genotype 4 Chronic Hepatitis C
- Associated Therapies
- -
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2019-01-09
- Target Recruit Count
- 70
- Registration Number
- NCT03004625
- Locations
- 🇨🇳
Kaohsiung Medical Universsity, Kaohsiung, Taiwan
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 207
- Registration Number
- NCT02496078
- Locations
- 🇷🇺
Local Institution, St.petersburg, Russian Federation
A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 88
- Registration Number
- NCT02323594
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Foundation for Liver Research
- Target Recruit Count
- 12
- Registration Number
- NCT02282709
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 297
- Registration Number
- NCT02123654
- Locations
- 🇯🇵
Local Institution, Saga, Japan
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 60
- Registration Number
- NCT02107365
- Locations
- 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷Hôpital de Haut Lévêque, Bordeaux Pessac, France
🇫🇷Hôpital Beaujon, Clichy, France
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 218
- Registration Number
- NCT01995266
- Locations
- 🇨🇳
Local Institution, Tainan, Taiwan
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 202
- Registration Number
- NCT01973049
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸Binghamton Gastroenterology Associates, Binghamton, New York, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT01886599
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸New Orleans Center For Clinical Research, Knoxville, Tennessee, United States
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 258
- Registration Number
- NCT01718145
- Locations
- 🇯🇵
Local Institution, Saitama, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.